How does Acanthopanax gracilistylus work in the body?

Acanthopanax gracilistylus contains active compounds including acanthoside B, eleutherosides, flavonoids, and saponins that exhibit anti-inflammatory and adaptogenic activity. These constituents modulate immune responses and stress pathways, supporting the herb's traditional actions of dispelling wind-dampness and tonifying liver and kidneys. The combined effects help strengthen musculoskeletal tissues and reduce inflammatory responses throughout the body. Evidence level: C.

Does Acanthopanax gracilistylus interact with any medications?

Limited clinical data exists on drug interactions for Acanthopanax gracilistylus. Due to its anti-inflammatory and adaptogenic properties, it may theoretically interact with immunosuppressive medications, anticoagulants, or antidiabetic drugs. Patients taking prescription medications should consult a qualified healthcare provider before adding this herb to their regimen. Evidence level: C.

What is the recommended dosage for Acanthopanax gracilistylus?

The standard adult dosage for Acanthopanax gracilistylus is 6-15 grams of dried root bark daily, typically prepared as a decoction. This dosing range is based on traditional Chinese medicine texts and clinical experience rather than standardized clinical trials. Individual needs may vary, so consultation with a qualified practitioner is recommended. Evidence level: Traditional.

Is Acanthopanax gracilistylus safe to take during pregnancy?

Acanthopanax gracilistylus is considered unsafe during pregnancy and should be avoided. Traditional Chinese medicine contraindications specifically warn against use in pregnancy. The active compounds may affect uterine function or fetal development, though specific clinical safety data remains limited. Pregnant or breastfeeding individuals should not use this herb without medical supervision. Evidence level: C.

What is Acanthopanax gracilistylus used for in traditional medicine?

In traditional Chinese medicine, Acanthopanax gracilistylus root bark is used to dispel wind-dampness, strengthen muscles and bones, and tonify the liver and kidneys. It is commonly prescribed for joint discomfort, weakness in the lower back and knees, and musculoskeletal conditions. Modern research has identified anti-inflammatory and adaptogenic properties supporting these traditional applications. Evidence level: C.

What are the side effects of Acanthopanax gracilistylus?

Acanthopanax gracilistylus may cause mild gastrointestinal changes including stomach discomfort or altered bowel movements in some individuals. The herb is contraindicated in cases of Yin deficiency with heat signs, which may manifest as night sweats, hot flashes, or irritability. Most adverse effects are mild and resolve upon discontinuation. Evidence level: C.

Acanthopanax gracilistylus (Acanthopanax gracilistylus)

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Acanthopanax gracilistylus is a deciduous plant of the Araliaceae family used in traditional Chinese medicine for its anti-inflammatory and bone-strengthening properties [PMID:38633273, PMID:36641105].

Contexte

Acanthopanax gracilistylus (also known as Eleutherococcus nodiflorus or Xi-zhu-wu-jia) is a deciduous plant in the Araliaceae family [PMID:38633273, PMID:36641105].

Usages traditionnels

In traditional Chinese medicine, the root bark is used to nourish the liver and kidneys, remove dampness, expel wind, and strengthen bones and tendons [PMID:38633273, PMID:36641105]. It has been used to treat paralysis, arthritis, rheumatism, lameness, body asthenia, fatigue, edema, beriberi, and liver diseases [PMID:36641105].

Composés actifs

Bioactive components include kaurenoic acid (main effective substance in root bark) [PMID:38633273], lupane-type triterpenoids and saponins (e.g., acankoreoside A, acantrifoside A, HLEDA) [PMID:29039503, PMID:28345393], acyl-quinic acids [PMID:37634270], chlorogenic acids [PMID:359101 la60], monoterpenoids [PMID:37683990], sesquiterpenoids (e.g., gracilistones A-D) [PMID:32319765, PMID:30243779], lignans [PMID:38972441], and polysaccharides [PMID:41751128].

Mécanisme d'action

Mechanisms include inhibition of the NF-κB signaling pathway [PMID:29671829, PMID:28345393], inhibition of COX-2 [PMID:37634270, PMID:37683990, PMID:38972441], and arrest of the cell cycle at the G0/G1 stage via reduction of phosphorylated Rb protein and Cdk2/Cdk4 expression [PMID:10804285, PMID:16248248].

Preuves cliniques

Preuve DInflammation

Various compounds (lupane triterpenoids, diterpenoids) inhibit the release of pro-inflammatory cytokines including TNF-α, IL-1β, and HMGB1 in vitro [PMID:29039503, PMID:25338180, PMID:28345393].

Preuve DFulminant Hepatitis

Pre-treatment with Acankoreanogenin A markedly reduced serum levels of TNF-α, IL-1β, HMGB1, ALT, and AST in mice models [PMID:21356341].

Preuve DDiabetes

Acankoreagenin increased insulin release in RIN-m5F cells and inhibited α-glucosidase, α-amylase, and PTP1B in vitro [PMID:29671829].

Preuve DTumor Growth

Extracts inhibited the proliferation of several human tumor cell lines (MT-2, Raji, HL-60, TMK-1, HSC-2) by inducing G0/G1 cell cycle arrest [PMID:10804285, PMID:16248248].

Preuve DOsteosarcoma

Gracilistylacid C and impressic acid exerted anti-osteosarcoma effects by inhibiting cell migration and vasculogenic mimicry in 143B cells in vitro [PMID:35085724].

Preuve D

Sécurité et effets indésirables

Consumption of Acanthopanax gracilistylus wine has been reported to lead to dark purple intestine [PMID:36524851].

Synthèse des preuves

The current evidence is primarily based on in vitro studies and animal models (Level D), focusing on phytochemical isolation and pharmacological activity. There are no human clinical trials (Level B) or meta-analyses (Level A) provided in the source data.

Sources PubMed

1.PMID: 35085724 (2022) — Antiosteosarcoma effects of novel 23-nor-3,4-seco-3-acetallupane triterpenoids from Acanthopanax gracilistylus W.W. Smith var. gracilistylus in 143B cells. · Fitoterapia
2.PMID: 38633273 (2024) — Full-length transcriptome profiling of Acanthopanax gracilistylus provides new insight into the kaurenoic acid biosynthesis pathway. · Physiology and molecular biology of plants : an international journal of functional plant biology
3.PMID: 29301264 (2018) — Lupane Triterpenes from the Leaves of Acanthopanax gracilistylus. · Molecules (Basel, Switzerland)
4.PMID: 36524851 (2022) — CONSUMPTION OF ACANTHOPANAX GRACILISTYLUS WINE LEADS TO DARK PURPLE INTESTINE. · Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
5.PMID: 37634270

Acanthopanax gracilistylus

Sources et citations